Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

6.92
-0.0200-0.29%
Post-market: 6.88-0.0400-0.58%19:09 EST
Volume:2.93M
Turnover:20.25M
Market Cap:1.41B
PE:-12.93
High:7.01
Open:6.98
Low:6.77
Close:6.94
52wk High:7.01
52wk Low:1.89
Shares:203.47M
Float Shares:115.00M
Volume Ratio:0.87
T/O Rate:2.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5350
EPS(LYR):-0.4838
ROE:-78.74%
ROA:-39.67%
PB:14.92
PE(LYR):-14.30

Loading ...

Savara Inc. to Participate in Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 04

Savara Closes $149.5 Million Public Offering

MT Newswires Live
·
Nov 01

Savara Inc. Faces Investor Class Action Over Securities Fraud Allegations

Reuters
·
Oct 31

BUZZ-U.S. STOCKS ON THE MOVE-Fiserv, CMS Energy, Moderna

Reuters
·
Oct 31

BUZZ-Biotech co Savara falls after $130 mln equity offering

Reuters
·
Oct 30

BRIEF-Savara Announces Pricing Of Public Offering At $4.20 Per Share

Reuters
·
Oct 30

Savara Inc - Prices Public Offering at $4.20 per Share

THOMSON REUTERS
·
Oct 30

Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Oct 30

Savara Secures $75 Million Royalty Financing from RTW for Potential MOLBREEVI Launch

Reuters
·
Oct 30

Savara Announces $75M Royalty Funding Agreement With Rtw to Support the Potential Launch of Molbreevi* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS
·
Oct 30

Savara Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Yasmine Wasfi

Reuters
·
Oct 23

Savara Inc. Releases Corporate Presentation Highlighting Development of New Therapies for Rare Respiratory Diseases, Including Autoimmune PAP

Reuters
·
Oct 17

Savara promotes Wasfi to Chief Medical Officer

TIPRANKS
·
Oct 17

Savara Announces Chief Medical Officer (Cmo) Transition

THOMSON REUTERS
·
Oct 17

Savara Inc. Faces Class Action Lawsuit Over Alleged Securities Fraud

Reuters
·
Oct 17

Mastek Ltd Sept-Quarter Consol Net Profit 974.5 Million Rupees

Reuters
·
Oct 16

Savara Inc. Publishes Corporate Presentation Highlighting Development of MOLBREEVI for Rare Respiratory Disease Autoimmune PAP

Reuters
·
Oct 15

Savara Inc publishes corporate presentation on new therapies for rare respiratory diseases including autoimmune PAP

Reuters
·
Oct 09

BRIEF-Savara Announces Encore Presentations Of Results From Phase 3 IMPALA-2 Clinical Trial Of Molgramostim Inhalation Solution

Reuters
·
Oct 03

Savara Inc. Announces Positive Phase 3 IMPALA-2 Trial Results for Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis at CHEST 2025

Reuters
·
Oct 03